CPSE:NOVO BPharmaceuticals
Assessing Novo Nordisk (CPSE:NOVO B) Valuation After Strong Early Uptake Of Oral Wegovy In The US
Novo Nordisk (CPSE:NOVO B) is back in focus after the US launch of its oral Wegovy pill, where early prescription data suggest a strong start that many investors view as a potential turning point.
See our latest analysis for Novo Nordisk.
The early strength of the Wegovy pill launch comes after a tough stretch, with Novo Nordisk reporting a 1-year total shareholder return decline of 37.4%, even as the 90-day share price return sits at 17% and the 5-year total shareholder return remains up...